Healthcare resource utilization with axi-cel vs. liso-cel in LBCL

In a poster presented during EHA 2026 poster, Prof Catherine Thieblemont and colleagies presented findings from a French real-world analysis evaluating the management of patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) treated with CAR T-cell therapy. The study included approximately 440 patients who received either axicabtagene ciloleucel (axi-cel) or lisocabtagene maraleucel (liso-cel), with the primary objective of comparing post-infusion management and healthcare resource utilization between the two CAR T-cell products.

The analysis demonstrated notable differences in patient management following infusion. Patients treated with axi-cel had a longer median hospital stay than those treated with liso-cel (17 vs. 10 days). Intensive care unit admission was also more frequent with axi-cel, occurring in 14.9% of patients compared with 1.9% of those receiving liso-cel. In addition, rehospitalization within the first three months after infusion was reported in 81.6% of patients treated with axi-cel versus 53.7% of patients treated with liso-cel.

Based on these real-world findings, Prof Thieblemont concluded that liso-cel is easier to manage than axi-cel in the second-line treatment of patients with R/R LBCL, with lower hospitalization requirements and reduced healthcare resource use.